이혁 교수
Hyeok Lee
성균관대학교 의학과 · 의학
연구실 소개
이혁 교수의 연구실은 소화기계 질환, 특히 장내 장벽 기능 이상과 관련된 면역 및 세포 생물학적 메커니즘을 중심으로 연구를 진행하고 있습니다. 특히 장내 비만세포의 역할, 장내 미생물-면역 상호작용, 그리고 암 치료를 위한 나노입자 기반 백신 전략 개발에 초점을 맞추고 있습니다. 최근에는 항우울제의 장기적 효과와 프로톤펌프차단제가 미네랄 대사에 미치는 영향에 대한 임상적 연구도 함께 수행하고 있습니다. 이는 기능성 장질환과 약물 유도성 대사 이상의 병태생리학적 기전을 규명하는 데 기여하고 있습니다.
연구 현황
연구 성과 추이
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
주요 논문
15This study demonstrated a positive correlation between the number of mucosal mast cells and intestinal permeability, suggesting that mucosal mast cells play an important role for increased intestinal permeability in patients with IBS-D.
Venlafaxine, an SNRI antidepressant, significantly improved symptoms in young adult patients with FCP.
WCS group showed comparable migration rate and significantly more durable long-term stent patency compared with UCS group for the palliation of GOO in patients with inoperable gastric cancer.
Immunotherapy can potentially treat cancers on a patient-dependent manner. Most of the efforts expended on anticancer vaccination parallel the efforts expended on prototypical immunization in infectious diseases. In this study, we designed and synthesized pH-responsive extracellular vesicles (EVs) coupled with hyaluronic acid (HA), 3-(diethylamino)propylamine (DEAP), monophosphoryl lipid A (MPLA), and mucin 1 peptide (MUC1), referred to as HDEA@EVAT. HDEA@EVAT potentiated the differentiation and
There is increasing evidence and case reports regarding proton pump inhibitor (PPI)-induced hypomagnesemia. Our study aimed to clarify the relationship between PPI use and serum magnesium levels and to specify high-risk patients. We retrospectively studied 112 consecutive patients aged 20 years or older who were treated with PPI for ≥30 days and whose serum magnesium levels were available for the PPI treatment period. We compared the mean level of serum magnesium of the enrolled patients with PP
BACKGROUND/AIMS: Combination therapy with peginterferon and ribavirin is a standard therapy for western patients with chronic hepatitis C; however, its efficacy remains unclear in East Asian patients. We evaluated the efficacy and safety of administering peginterferon alfa-2a plus ribavirin in native Korean patients with chronic hepatitis C. METHODS: Seventy-five patients with detectable HCV RNA (52.0% male, median age: 50.8 years) were eligible for the study. The patients were treated with pegi
대표 연구 분야
이혁 교수의 연구를 Nubint에서 더 깊이 살펴보세요
이 연구실의 논문을 앱에서 열어 AI와 함께 읽고, 핵심을 요약하고, 내 글에 인용하세요.